Examiner: DAHLIN, HEATHER RAQUEL

Tech Center 1600 • Art Units: 1628 1629

This examiner grants 41% of resolved cases

Analysis

Heather Raquel Dahlin is an examiner in Tech Center 1600 and Art Unit 1628 with 163 resolved cases. Her allowance rate is 41.1%, but the interview lift is 47.5%. This indicates that interviews are an effective strategy for improving the 41.1% allowance rate. This 47.5% lift is a factor for the 163 resolved cases analyzed, suggesting that direct engagement is beneficial.

Practitioners should account for the 1219-day timeline when working with this examiner in Tech Center 1600. The 47.5% lift from interviews is a tool for overcoming the 41.1% baseline success rate. For the 163 resolved cases, the 1219-day median pendency provides an expectation for the duration of the prosecution process. Prioritizing interviews is a way to navigate the challenges of Art Unit 1628 and secure a grant. These metrics define the examination environment under her review.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

41.1%

Allow Rate

-18.9% vs TC avg

224

Total Applications

+47.5%

Interview Lift

1219

Avg Prosecution Days

Based on 163 resolved cases, 2023–2026

Rejection Statute Breakdown

4.3%

§101 Eligibility

19.5%

§102 Novelty

35.3%

§103 Obviousness

24.5%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
17612074	Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain	Final Rejection	King's College London
18623722	EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE	Non-Final OA	Yale University
18255076	NEW INDAZOLE DERIVATIVES	Final Rejection	Hoffmann-La Roche Inc.
18035152	Use of 5-HT3-Targeting Drugs for Treatment of Acute Kidney Injury	Final Rejection	University of Pittsburgh-Of the Commonwealth System of Higher Education
17993922	METHOD FOR SCREENING MARKERS FOR PREDICTING PROGNOSIS OF RENAL CELL CARCINOMA USING TRANSCRIPTOMIC ANALYSIS	Non-Final OA	Gwangju Institute of Science and Technology
18279708	CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES	Final Rejection	DOMPE' FARMACEUTICI SPA
17999441	Compositions and Methods for Treating Cocaine, Nicotine, and Methamphetamine Dependence	Final Rejection	Babak Behnam

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy